Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Antiangiogenic properties of substituted (Z)-(±)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-ol/one analogs and their derivatives.

Venkateswaran A, Reddy YT, Sonar VN, Muthusamy V, Crooks PA, Freeman ML, Sekhar KR.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7323-6. doi: 10.1016/j.bmcl.2010.10.060. Epub 2010 Oct 21.

2.

Novel substituted (Z)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-one and (Z)-(+/-)-2-(N-benzylindol-3-ylmethylene)quinuclidin-3-ol derivatives as potent thermal sensitizing agents.

Sonar VN, Thirupathi Reddy Y, Sekhar KR, Sasi S, Freeman ML, Crooks PA.

Bioorg Med Chem Lett. 2007 Dec 15;17(24):6821-4. Epub 2007 Oct 17.

3.

The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteins.

Venkateswaran A, Friedman DB, Walsh AJ, Skala MC, Sasi S, Rachakonda G, Crooks PA, Freeman ML, Sekhar KR.

Invest New Drugs. 2013 Jun;31(3):535-44. doi: 10.1007/s10637-012-9884-9. Epub 2012 Oct 9.

4.

Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature.

Geng L, Rachakonda G, Morré DJ, Morré DM, Crooks PA, Sonar VN, Roti JL, Rogers BE, Greco S, Ye F, Salleng KJ, Sasi S, Freeman ML, Sekhar KR.

FASEB J. 2009 Sep;23(9):2986-95. doi: 10.1096/fj.09-130005. Epub 2009 Apr 24.

5.

Aplysinopsin analogs: Synthesis and anti-proliferative activity of substituted (Z)-5-(N-benzylindol-3-ylmethylene)imidazolidine-2,4-diones.

Thirupathi Reddy Y, Narsimha Reddy P, Koduru S, Damodaran C, Crooks PA.

Bioorg Med Chem. 2010 May 15;18(10):3570-4. doi: 10.1016/j.bmc.2010.03.054. Epub 2010 Mar 27.

6.

3-Heteroaryl-substituted quinuclidin-3-ol and quinuclidin-2-ene derivatives as muscarinic antagonists. Synthesis and structure-activity relationships.

Nilsson BM, Sundquist S, Johansson G, Nordvall G, Glas G, Nilvebrant L, Hacksell U.

J Med Chem. 1995 Feb 3;38(3):473-87.

PMID:
7853341
7.

Preparation of novel meta- and para-substituted N-benzyl protected quinuclidine esters and their resolution with butyrylcholinesterase.

Primožič I, Bolant M, Ramić A, Tomić S.

Molecules. 2012 Jan 16;17(1):786-95. doi: 10.3390/molecules17010786.

8.
9.

2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists.

Clark RD, Miller AB, Berger J, Repke DB, Weinhardt KK, Kowalczyk BA, Eglen RM, Bonhaus DW, Lee CH, Michel AD, et al.

J Med Chem. 1993 Sep 3;36(18):2645-57.

PMID:
8410977
10.

Anti-angiogenic effects of a nutrient mixture on human umbilical vein endothelial cells.

Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M.

Oncol Rep. 2005 Dec;14(6):1399-404.

PMID:
16273231
11.

Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents.

Abadi AH, Abou-Seri SM, Abdel-Rahman DE, Klein C, Lozach O, Meijer L.

Eur J Med Chem. 2006 Mar;41(3):296-305. Epub 2006 Feb 21.

PMID:
16494969
12.

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.

Cell Physiol Biochem. 2011;27(5):565-74. doi: 10.1159/000329978. Epub 2011 Jun 15.

13.

Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410).

Cai YC, Zou Y, Ye YL, Sun HY, Su QG, Wang ZX, Zeng ZL, Xian LJ.

Invest New Drugs. 2011 Apr;29(2):300-11. doi: 10.1007/s10637-009-9366-x. Epub 2009 Dec 11.

PMID:
20012336
14.

Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.

Naito R, Yonetoku Y, Okamoto Y, Toyoshima A, Ikeda K, Takeuchi M.

J Med Chem. 2005 Oct 20;48(21):6597-606.

PMID:
16220976
15.

Design, synthesis, and anti-proliferative evaluation of [1,1'-biphenyl]-4-ols as inhibitor of HUVEC migration and tube formation.

Ran Y, Ma L, Wang X, Chen J, Wang G, Peng A, Chen L.

Molecules. 2012 Jul 5;17(7):8091-104. doi: 10.3390/molecules17078091.

16.

Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities.

Chillemi F, Francescato P, Ragg E, Cattaneo MG, Pola S, Vicentini L.

J Med Chem. 2003 Sep 11;46(19):4165-72.

PMID:
12954068
17.

Conformation-activity relationship on novel 4-pyridylmethylthio derivatives with antiangiogenic activity.

Honda T, Tajima H, Kaneko Y, Ban M, Inaba T, Takeno Y, Okamoto K, Aono H.

Bioorg Med Chem Lett. 2008 May 1;18(9):2939-43. doi: 10.1016/j.bmcl.2008.03.068. Epub 2008 Mar 29.

PMID:
18420406
18.

Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.

Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Warnke LA.

Bioorg Med Chem. 2008 May 15;16(10):5514-28. doi: 10.1016/j.bmc.2008.04.019. Epub 2008 Apr 14.

19.

New vandetanib analogs: fused tricyclic quinazolines with antiangiogenic potential.

Conconi MT, Marzaro G, Guiotto A, Urbani L, Zanusso I, Tonus F, Tommasini M, Parnigotto PP, Chilin A.

Invest New Drugs. 2012 Apr;30(2):594-603. doi: 10.1007/s10637-010-9621-1. Epub 2010 Dec 24.

PMID:
21184131
20.

Synthesis of symmetrical bis-alkynyl or alkyl pyridine and thiophene derivatives and their antiangiogenic activities.

Ahn CM, Shin WS, Bum Woo H, Lee S, Lee HW.

Bioorg Med Chem Lett. 2004 Aug 2;14(15):3893-6.

PMID:
15225692

Supplemental Content

Support Center